The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies
Open accessAbstract
The management of the central nervous system (CNS) disorders is challenging, due to the need of drugs to cross the blood‒brain barrier (BBB) and reach the brain. Among the various strategies that have been studied to circumvent this challenge, the use of the intranasal route to transport drugs from the nose directly to the brain has been showing promising results. In addition, the encapsulation of the drugs in lipid-based nanocarriers, such as solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) or nanoemulsions (NEs), can improve nose-to-brain transport by increasing the bioavailability and site-specific delivery. This review provides the state-of-the-art of in vivo studies with lipid-based nanocarriers (SLNs, NLCs and NEs) for nose-to-brain delivery. Based on the literature available from the past two years, we present an insight into the different mechanisms that drugs can follow to reach the brain after intranasal administration. The results of pharmacokinetic and pharmacodynamics studies are reported and a critical analysis of the differences between the anatomy of the nasal cavity of the different animal species used in in vivo studies is carried out. Although the exact mechanism of drug transport from the nose to the brain is not fully understood and its effectiveness in humans is unclear, it appears that the intranasal route together with the use of NLCs, SLNs or NEs is advantageous for targeting drugs to the brain. These systems have been shown to be more effective for nose-to-brain delivery than other routes or formulations with non-encapsulated drugs, so they are expected to be approved by regulatory authorities in the coming years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Ahmad, N., Ahmad, R., Naqvi, A. A., Alam, A., Ashafaq, M., Rub, R. A., & Ahmad, F. J. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1337024 · Cited by 76
RetractedGadhave, D. G., Tagalpallewar, A. A., & Kokare, C. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-018-1213-y · Cited by 49
RetractedAhmad, N., Ahmad, R., Alam, M. A., Ahmad, F. J., & Amir, M. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2018.1489826 · Cited by 46
RetractedDanaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020057 · Cited by 4,832
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products
Pardeike, J., Hommoss, A., & Müller, R. H. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.10.003 · Cited by 1,478
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239
Nasal drug delivery—possibilities, problems and solutions
Illum, L. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00363-2 · Cited by 1,102
Mohammadi-Samani, S., & Ghasemiyeh, P. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.235156 · Cited by 970
Thorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Cited by
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678
Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier
Zha, S., Liu, H., Li, H., Li, H., Wong, K.-L., & All, A. H. (2024) · ACS Nano · doi:10.1021/acsnano.3c10674 · Cited by 378
Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs
Liu, Y., Liang, Y., Yuhong, J., Xin, P., Han, J. L., Du, Y., Yu, X., Zhu, R., Zhang, M., Chen, W., et al. (2024) · Drug Design, Development and Therapy · doi:10.2147/dddt.s447496 · Cited by 365
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles
Formica, M. L., Real, D. A., Picchio, M. L., Catlin, E., Donnelly, R. F., & Paredes, A. J. (2022) · Applied Materials Today · doi:10.1016/j.apmt.2022.101631 · Cited by 282
Khan, S., Sharma, A., & Jain, V. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.056 · Cited by 259
Koo, J., Lim, C., & Oh, K. T. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s439181 · Cited by 174
Wu, H., Zhou, Y., Wang, Y., Tong, L., Wang, F., Song, S., Xu, L., Liu, B., Yan, H., & Sun, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.717192 · Cited by 90
Shehata, M. K., Ismail, A. A., & Kamel, M. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s417928 · Cited by 55
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Metadata
- Authors
- Costa, C. P., Moreira, J. N., Sousa Lobo, J. M., & Silva, A. C.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 11
- Issue
- 4
- Pages
- 925-940
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3138364107
- Cited by
- 303
- References
- 84
- FWCI
- 15.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.